Literature DB >> 12614161

Nature of full-length HMGB1 binding to cisplatin-modified DNA.

Yongwon Jung1, Stephen J Lippard.   

Abstract

HMGB1, a highly conserved non-histone DNA-binding protein, interacts with specific DNA structural motifs such as those encountered at cisplatin damage, four-way junctions, and supercoils. The interaction of full-length HMGB1, containing two tandem HMG box domains and a C-terminal acidic tail, with cisplatin-modified DNA was investigated by hydroxyl radical footprinting and electrophoretic gel mobility shift assays. The full-length HMGB1 protein binds to DNA containing a 1,2-intrastrand d(GpG) cross-link mainly through domain A, as revealed by footprinting, with a dissociation constant K(d) of 120 nM. Site-directed mutagenesis of intercalating residues in both HMG domains A and B in full-length HMGB1 further supports the conclusion that only one HMG box domain is bound to the site of cisplatin damage. Interaction of the C-terminal tail with the rest of the HMGB1 protein was examined by EDC cross-linking experiments. The acidic tail mainly interacts with domain B and linker regions rather than domain A in HMGB1. These results illuminate the respective roles of the tandem HMG boxes and the C-terminal acidic tail of HMGB1 in binding to DNA and to the major DNA adducts formed by the anticancer drug cisplatin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12614161     DOI: 10.1021/bi026972w

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  36 in total

1.  Debio 0507 primarily forms diaminocyclohexane-Pt-d(GpG) and -d(ApG) DNA adducts in HCT116 cells.

Authors:  C L King; S Ramachandran; S G Chaney; L Collins; J A Swenberg; K E DeKrafft; W Lin; L Cicurel; M Barbier
Journal:  Cancer Chemother Pharmacol       Date:  2011-10-04       Impact factor: 3.333

2.  Conformation of DNA GG intrastrand cross-link of antitumor oxaliplatin and its enantiomeric analog.

Authors:  Jaroslav Malina; Olga Novakova; Marie Vojtiskova; Giovanni Natile; Viktor Brabec
Journal:  Biophys J       Date:  2007-08-17       Impact factor: 4.033

3.  Effect of in vivo post-translational modifications of the HMGB1 protein upon binding to platinated DNA: a molecular simulation study.

Authors:  Wenping Lyu Lv; Fabio Arnesano; Paolo Carloni; Giovanni Natile; Giulia Rossetti
Journal:  Nucleic Acids Res       Date:  2018-12-14       Impact factor: 16.971

4.  Redox state-dependent interaction of HMGB1 and cisplatin-modified DNA.

Authors:  Semi Park; Stephen J Lippard
Journal:  Biochemistry       Date:  2011-02-28       Impact factor: 3.162

5.  Enhancement of DNA flexibility in vitro and in vivo by HMGB box A proteins carrying box B residues.

Authors:  Nadia T Sebastian; Emily M Bystry; Nicole A Becker; L James Maher
Journal:  Biochemistry       Date:  2009-03-17       Impact factor: 3.162

6.  Binding interaction of HMGB4 with cisplatin-modified DNA.

Authors:  Semi Park; Stephen J Lippard
Journal:  Biochemistry       Date:  2012-08-17       Impact factor: 3.162

Review 7.  Interactions of high mobility group box protein 1 (HMGB1) with nucleic acids: Implications in DNA repair and immune responses.

Authors:  Pooja Mandke; Karen M Vasquez
Journal:  DNA Repair (Amst)       Date:  2019-09-16

8.  Single and double box HMGB proteins differentially destabilize nucleosomes.

Authors:  Micah J McCauley; Ran Huo; Nicole Becker; Molly Nelson Holte; Uma M Muthurajan; Ioulia Rouzina; Karolin Luger; L James Maher; Nathan E Israeloff; Mark C Williams
Journal:  Nucleic Acids Res       Date:  2019-01-25       Impact factor: 16.971

Review 9.  Targeting Chromosomal Architectural HMGB Proteins Could Be the Next Frontier in Cancer Therapy.

Authors:  Anirban Mukherjee; Karen M Vasquez
Journal:  Cancer Res       Date:  2020-03-09       Impact factor: 12.701

10.  The yeast high mobility group protein HMO2, a subunit of the chromatin-remodeling complex INO80, binds DNA ends.

Authors:  Sreerupa Ray; Anne Grove
Journal:  Nucleic Acids Res       Date:  2009-09-02       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.